CoChat

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

Published version of a preprint

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

Purpose: KRAS-mutant lung cancers have been recalcitrant to treatments including those targeting the MAPK pathway. Covalent inhibitors of KRAS p.G12C allele allow for direct and specific inhibition of mutant KRAS in cancer cells. However, as for other targeted therapies, the therapeutic potential of these inhibitors can be impaired by intrinsic resistance mechanisms. Therefore, combination strategies are likely needed to improve efficacy. Experimental Design: To identify strategies to maximally leverage direct KRAS inhibition we defined the response of a panel of NSCLC models bearing the KRAS G12C–activating mutation in vitro and in vivo. We used a second-generation KRAS G12C inhibitor, ARS1620 with improved bioavailability over the first generation. We analyzed KRAS downstream effectors signaling to identify mechanisms underlying differential response. To identify candidate combination strategies, we performed a high-throughput drug screening across 112 drugs in combination with ARS1620. We validated the top hits in vitro and in vivo including patient-derived xenograft models. Results: Response to direct KRAS G12C inhibition was heterogeneous across models. Adaptive resistance mechanisms involving reactivation of MAPK pathway and failure to induce PI3K–AKT pathway inactivation were identified as likely resistance events. We identified several model-specific effective combinations as well as a broad-sensitizing effect of PI3K-AKT–mTOR pathway inhibitors. The G12Ci+PI3Ki combination was effective in vitro and in vivo on models resistant to single-agent ARS1620 including patient-derived xenografts models. Conclusions: Our findings suggest that signaling adaptation can in some instances limit the efficacy of ARS1620 but combination with PI3K inhibitors can overcome this resistance.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-18-0368

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

34 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 39 references

Cited by

See all 259

Metadata

Authors
Misale, S., Fatherree, J. P., Cortez, E., Li, C., Bilton, S., Timonina, D., Myers, D. T., Lee, D., Gomez-Caraballo, M., Greenberg, M., Nangia, V., Greninger, P., Egan, R. K., McClanaghan, J., Stein, G. T., Murchie, E., Zarrinkar, P. P., Janes, M. R., Li, L.-S., Liu, Y., Hata, A. N., & Benes, C. H.
Affiliations
  • Harvard University (US)
  • 1Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Wellspring Biosciences (United States) (US)
  • Kura Oncology (United States) (US)
Corresponding author
  • Hata, Aaron N.
  • Benes, Cyril H.
Venue
Clinical Cancer Research
Published
2019-01-15
Volume
25
Issue
2
Pages
796-807
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2895923466
Cited by
259
References
39
Citations by year
2026: 25 · 2025: 35 · 2024: 32 · 2023: 33 · 2022: 40 · 2021: 46 · 2020: 33 · 2019: 15
FWCI
17.71
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • American Cancer Society (SU2C-AACRDT17-15)
  • Wellcome Trust (102696)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
KRAS G12C, non-small cell lung cancer, PI3K inhibition, combination therapy, drug resistance, MAPK pathway reactivation, PI3K/AKT/mTOR pathway, patient-derived xenografts, high-throughput drug screening, KRAS-mutant lung cancer
MeSH terms
Phosphoinositide-3 Kinase Inhibitors, Alleles, Animals, Drug Screening Assays, Antitumor, Humans, Mutation, Signal Transduction, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Gene Silencing, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-0368
The paper
Misale, S., Fatherree, J. P., Cortez, E., Li, C., Bilton, S., Timonina, D., Myers, D. T., Lee, D., Gomez-Caraballo, M., Greenberg, M., Nangia, V., Greninger, P., Egan, R. K., McClanaghan, J., Stein, G. T., Murchie, E., Zarrinkar, P. P., Janes, M. R., Li, L.-S., . . . Benes, C. H. (2019). KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-0368

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.